Li, L. (2025). Disproportionate adverse event signals of selumetinib in neurofibromatosis type I: Insights from FAERS. Frontiers in pharmacology, 15, 1454418. https://doi.org/10.3389/fphar.2024.1454418
Citácia podle Chicago (17th ed.)Li, Lin. "Disproportionate Adverse Event Signals of Selumetinib in Neurofibromatosis Type I: Insights from FAERS." Frontiers in Pharmacology 15 (2025): 1454418. https://doi.org/10.3389/fphar.2024.1454418.
Citácia podľa MLA (8th ed.)Li, Lin. "Disproportionate Adverse Event Signals of Selumetinib in Neurofibromatosis Type I: Insights from FAERS." Frontiers in Pharmacology, vol. 15, 2025, p. 1454418, https://doi.org/10.3389/fphar.2024.1454418.
Upozornenie: Tieto citáce sú generované automaticky. Nemusia byť úplne správne podľa citačných pravidiel..